Market intelligence workspace
Market intelligence workspace
Recent disclosed activity connected to public officials.
Premium crowd and conversation intelligence.
Notable contracts and premium concentration.
Large institutional position updates.
Core valuation, range, and trading metrics.
Moderna, Inc. Common Stock
Updated Aug 21, 5:26 AM UTCFree market coverage from the current news feed.
Moderna and Merck announced positive Phase 3 clinical trial results for intismeran, an mRNA-based cancer therapy designed to activate anti-tumor immune responses in melanoma patients. The experimental treatment met its primary endpoint of recurrence-free survival when combined with Merck's Keytruda immunotherapy. The companies plan to present additional data and seek regulatory approval, positioning them to capture a larger share of the $275 billion global oncology market by 2030.
Read storyModerna and Merck announced successful Phase 3 trial results for a personalized mRNA cancer vaccine combined with Merck's Keytruda immunotherapy. The treatment showed melanoma patients experienced longer periods before cancer recurrence and reduced spread compared to Keytruda alone. This marks the first Phase 3 success for mRNA cancer therapy and individualized neoantigen therapy, with both companies planning to present findings to regulators.
Read storyThe global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.
Read storyModerna's stock has surged nearly 90% in 2026, driven by positive FDA news about its flu vaccine mRNA-1010 in June. However, the rally appears unjustified as the vaccine is unlikely to generate significant revenue ($1B by 2028) and the company faces fundamental challenges including $3.4B in operating losses over the trailing 12 months, declining revenue, and dependence on COVID vaccine sales. With a $20B+ market cap and limited compelling growth catalysts beyond the experimental cancer vaccine mRNA-4157, the stock appears overvalued for its risk profile.
Read storyIXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.
Read storyModerna stock has surged 109% in 2026 as the biotech company successfully transitions from a coronavirus vaccine player to a multi-product company. With cost reductions of 26%, three approved products, and promising late-stage candidates in oncology and rare diseases, analysts view it as increasingly investable. Though the stock has pulled back 24% from its July peak, it remains a buy for long-term investors, though cautious investors may wait for further progress on pipeline candidates.
Read storyThe strongest signal is that options flow shows a strong lean toward calls, while several large institutions have recently filed buys and news around the cancer therapy trial has been positive. The wider picture looks mixed to slightly bullish because that support is offset by a steep daily drop, a split analyst view, and the CEO’s recent filing activity showing both buys and sells.
Generated Aug 21, 2026Reported EPS compared with analyst estimates.